Endpoint Health, Inc. Market Research Report
Company Overview
Endpoint Health, Inc., based in Palo Alto, California, is a leader in the field of precision medicine. Located at 855 El Camino Real, Suite 13A, Palo Alto, CA 94301, the company is pioneering a Precision-First™ therapeutics approach, moving beyond the traditional molecule-first drug development model. Their mission is to develop customized medical treatments tailored to the unique biology and disease profiles of individual patients, specifically focusing on immune-mediated diseases. Their goal is to foster a future where all patients receive optimized treatment based on their distinct biological needs.
Key Information
- Company Vision: Deliver the best possible personalized treatment for every patient.
- Website: [Endpoint Health](https://endpointhealth.com/)
Management Team
- Jason Springs: Co-Founder, CEO
- Diego Rey, PhD: Co-Founder, CSO
- Leonardo Teixeira, PhD: Co-Founder, COO
- Ajay Duggal, MD: Chief Medical Officer
- David Leonard: Chief Administrative Officer
- Penny Toren: SVP, Regulatory Affairs
- Julie Friedman: VP, Therapeutics Operations & Program Management
- Tim Foley: VP, Head of Therapeutic Business Development
- Mona Khalid: VP, Portfolio Strategy & Scientific Affairs
- Kristen Taylor Meadows, PhD: VP, Discovery & Translational Science
- Pamela Ha: VP, Finance
- Norris Abella: VP, IVD Development
- Akbar Khan: VP, Clinical Operations
Financial Overview
Endpoint Health has raised $52 million across two funding rounds. Their investor network includes AME Cloud Ventures and Mayfield, which are crucial for their ongoing development of a precision immunology pipeline.
Strategic Initiatives and Programs
The company is dedicated to innovative precision immunology programs, specifically targeting inflammation in autoimmune diseases. Their strategy integrates therapeutics, therapy-guiding tests, and artificial intelligence (AI) to develop precision therapies as part of their comprehensive research and development efforts.
Noteworthy Programs and Collaborations
- Precision Immunology Program: Focuses on tissue factor-mediated inflammation in autoimmune diseases.
- Global Collaboration and Licensing Agreements: Fostered to innovate and market solutions in therapeutics.
Research and Development Initiatives
Endpoint Health's commitment to expanding and enhancing its precision immunology pipeline focuses on targeted therapies and companion diagnostics addressing unmet needs in acute and chronic immune-mediated diseases.
Contact Information
- General Inquiries: [info@endpointhealth.com](mailto:info@endpointhealth.com)
- Media Inquiries: [media@endpointhealth.com](mailto:media@endpointhealth.com)
Competitor Profiling
Industry Overview
Endpoint Health operates within a dynamic biotech and health technology sector, specializing in areas like electronic health records, health informatics, and immunology. The company has distinguished itself with three patents, showcasing a dedication to technological innovation.
Competitors and Alternatives
Endpoint Health faces competition from a diverse range of companies in the biotechnology and healthcare technology sectors:
1. Codiak Biosciences
2. Polyplus-transfection
3. Acorda Therapeutics
4. Vcanbio Cell & Gene Engineering
5. Biogen
6. UCB
7. Grifols
8. Arbor Biotechnologies
9. Advanced Cell Diagnostics
10. Biocept
These competitors reflect Endpoint Health's involvement across the biotechnological spectrum.
Alternative Technologies
In the realm of software and solution platforms, Endpoint Health's offerings are compared against:
- JumpCloud Directory Platform
- ACMP Suite
- VantageMDM
- Scalefusion
- Syxsense
This variety provides clients with a broad selection of options to meet specific needs.
Financial Performance and Industry Standing
Although specific revenue figures are undisclosed, Endpoint Health maintains a significant presence within the health technology sector due to its innovative patent filings and diverse competition.
